MENU
+Compare
ATOS
Stock ticker: NASDAQ
AS OF
Jan 15, 04:59 PM (EDT)
Price
$0.58
Change
-$0.02 (-3.33%)
Capitalization
77.89M

ATOS Atossa Therapeutics Forecast, Technical & Fundamental Analysis

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology... Show more

ATOS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ATOS with price predictions
Jan 14, 2026

ATOS sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for ATOS moved below the 200-day moving average on December 26, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 17, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ATOS as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ATOS moved below its 50-day moving average on December 12, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATOS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ATOS broke above its upper Bollinger Band on December 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ATOS entered a downward trend on January 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ATOS's RSI Indicator exited the oversold zone, of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where ATOS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ATOS just turned positive on January 08, 2026. Looking at past instances where ATOS's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ATOS advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.564) is normal, around the industry mean (27.929). P/E Ratio (0.000) is within average values for comparable stocks, (51.397). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.899). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.547).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ATOS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ATOS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ATOS is expected to report earnings to fall 4.71% to -6 cents per share on April 01

Atossa Therapeutics ATOS Stock Earnings Reports
Q4'25
Est.
$-0.07
Q3'25
Missed
by $0.01
Q2'25
Missed
by $0.01
Q1'25
Beat
by $0.02
Q4'24
Beat
by $0.02
The last earnings report on November 12 showed earnings per share of -7 cents, missing the estimate of -5 cents. With 1.01M shares outstanding, the current market capitalization sits at 77.89M.
A.I. Advisor
published General Information

General Information

a manufacturer of products for breast cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
107 Spring Street
Phone
+1 206 588-0256
Employees
12
Web
https://www.atossatherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
COSAF0.310.03
+10.33%
COSA RES CORP.
INDOY5.07N/A
N/A
Indorama Ventures Public Company Limited
LBGUF45.79N/A
N/A
LE Lundbergfoeretagen AB
NDATF0.01N/A
N/A
NDATALYZE CORP.
CAPFF1.55N/A
N/A
Capital Limited

ATOS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with AXON. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-5.30%
AXON - ATOS
42%
Loosely correlated
-1.92%
RGNX - ATOS
39%
Loosely correlated
-0.66%
MGX - ATOS
38%
Loosely correlated
+0.58%
RXRX - ATOS
38%
Loosely correlated
+3.41%
VYGR - ATOS
36%
Loosely correlated
+2.74%
More